AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06004141 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laguna Health
Description: Laguna Health is a novel behavioral coaching intervention (Laguna Health) that provides supportive care to patients with cancer who are discharged from the hospital and their caregivers. The intervention includes four components: 1) behavioral coaching with a Laguna Health recovery coach; 2) digital psycho-educational content tailored to the needs of patients with cancer; 3) summary of post-discharge care tasks; and 4) behavioral strategies to promote self-efficacy.
Study NCT05372341 — intervention group
Intervention type: OTHER
Intervention: descriptive
Description: posotcovid patients will be elective surgery postoperative outcomes
Study NCT05593159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cention N
Description: The cavity will be restored using cention N followed by light curing for 10sec (1,000 mW/cm2)
Study NCT01511835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inositol + folic acid
Description: 2000 mg of inositol+200mcg of folic acid; 2 per diem
Study NCT01511835 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inositol + folic acid
Description: 600 mg of inositol + 200mcg of folic acid; 2 cp per diem
Study NCT01511835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid 400mcg; 1 cp/die
Study NCT06015802 — intervention group
Intervention type: OTHER
Intervention: diagnosed and treated reasonably according to the clinical guidelines and clinical pathways
Description: The clinical data and biological specimens of the selected patients were collected, and the patients were diagnosed and treated reasonably according to the clinical guidelines and clinical pathways. The prognosis and outcome of the disease within 5 years after discharge were observed.
Study NCT06490419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrolipolysis
Description: Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, with physiological nutrient content: carbohydrates-50%, proteins-20%, fats-30% and fiber daily consumption of 30 - 40 g in dry form (grain and vegetables). Calorie distribution: breakfast-40%, lunch-40%, dinner-20%. Behavioral therapy to correct eating disorders: diary of food and lifestyle, motivational phone calls every week~Electrolipolysis:~the participants will receive electrolipolysis applied to abdomen, thigh and gluteal regions, 3 sessions/week, for 3 months, 60 minutes/session; 30 minutes on the abdomen and thigh and 30 minutes on gluteal region. the device will be set to cause a contraction for 4 seconds followed by a relaxation for 4 seconds with a pulse width of 400 microseconds and a frequency of 20 pulses per minute.
Study NCT06490419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound cavitation
Description: Hypocaloric diet:~All patients were prescribed balanced hypocaloric diet (1200 kcal/day) by the nutrition specialist, as in the electrolipolysis group.~ultrasound cavitation (UC): The participants will be treated by UC on the abdomen for 30 minutes, two sessions per week for 3 months. From standing position, the abdominal area of each patient will be divided transversally into 3 parts; part I: from the xiphoid process to 3 cm above the umbilicus, part II: from 3cm above the umbilicus to 2 cm below the umbilicus and part III: from 2 cm below the umbilicus to the pubic bone. Vertically, each part will be divided into right and left segments in relation to the linea alba, forming a total of 6 abdominal segments.~The program of cavitation; frequency (40 kHz) will be chosen, the time will be adjusted at 30 minutes. The cavitational head will be, then, moved very slowly on each abdominal segment in a small circular movement for 5 minutes.
Study NCT05349578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: swab RUT
Description: rapid urease test using swab instead of biopsied tissue
Study NCT05349578 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: swab RUT
Description: rapid urease test using swab instead of biopsied tissue
Study NCT05593159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dentin roughness
Description: Using a round carbide bur size 14/16, (H1SEM.204.014 VPE5 or H1SEM.204.016 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece. (No bevel preparation will be made)
Study NCT05593159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gingival retentive groove preparation
Description: Using size-010 round carbide bur (H1SEM.205.010 VPE 5, Komet Dental, Lemgo, Germany) on a low-speed handpiece.
Study NCT06554418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communities Care
Description: Communities Care is a violence prevention program targeting social norms and behavioral change
Study NCT06446726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients will undergo two cycles of immunotherapy, each cycle lasting 21 days. Day 3 and Day 24: Tislelizumab, fixed dose of 200 mg
Study NCT06446726 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Patients will undergo two cycles of low-dose radiotherapy. Day 1/2 and Day 22/23: Low-dose radiotherapy (8 Gy/4f)
Study NCT06446726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Nab-paclitaxel 260 mg/m2
Study NCT06446726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Patients will undergo two cycles of chemotherapy. Day 3 and Day 24: Cisplatin 75 mg/m2.
Study NCT05143658 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LLS versus LP
Description: Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
Study NCT05143658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LLS versus LP
Description: Procedure: Laparoscopic repair of anterior and apical pelvic organ prolapse Surgical correction of anterior and apical pelvic organ prolapse by laparoscopy
Study NCT05862610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib plus chemotherapy
Description: Trilaciclib: 240mg/m2 IV d1,within 4h before chemotherapy epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
Study NCT05862610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: epirubicin: 100mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles cyclophosphamide:600mg/m2 IV d1,Q2W/Q3W (decided by researchers),4 cycles albumin-bound paclitaxel:100mg/m2 IV d1,8,15,Q3W,4cycles
Study NCT04767698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: 200 mg SC weekly for 36 months
Study NCT04767698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Short-course Ocrelizumab
Description: 300 mg, two infusions two weeks apart and then 600 mg as a single infusion after six months (only one time) (total of two courses of treatment)
Study NCT04767698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continued Ocrelizumab
Description: 300 mg, two infusions two weeks apart and then 600 mg as a single infusion every six months for a total of 36 months
Study NCT05264012 — intervention group
Intervention type: PROCEDURE
Intervention: Neurosurgery
Description: Neurosurgery
Study NCT05515900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium
Description: Daily sodium supplementation of 2000 mg.
Study NCT05515900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB
Description: Daily HMB supplementation of 3 g.
Study NCT05515900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills that will be identical to sodium or HMB supplementations
Study NCT05485389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation based learning
Description: An educational methodology that aims to improve participants' attitudes towards the elderly and their perception of individualized care.
Study NCT06115993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHB-137 injection
Description: AHB-137 injection will be administered subcutaneously.
Study NCT06115993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered subcutaneously.
Study NCT06167954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXPLORER
Description: 8 sessions of use of the device in the home and the community of the participants
Study NCT05307939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV ctDNA Assay
Description: HPV ctDNA evaluation will be completed using NavDx which is a validated digital droplet PCR (ddPCR) assay that targets primers and hydrolysis probes to specifically detect amplicons within the E6 and E7 genes encoded by high-risk HPV strain 16, and the E7 gene for high-risk HPV strains: 18, 31, 33, and 35.
Study NCT05307939 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Studies
Description: Research MRI studies will be acquired at Memorial Sloan Kettering using a fast multi-phase spoiled gradient echo sequence. A Gadolinium-based agent will be used for DCE-MRI studies.
Study NCT05307939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EORTC QLQ H&N 35 and C30
Description: The EORTC QLQ H\&N 35 s a validated 35-item site specific assessment tool. The module uses 7 multi-item scales to measure problems with swallowing, senses, speech, social eating and social contact. In addition, 11 single-item scales are utilized in assessing problems with teeth, mouth opening, dry mouth, sticky saliva, coughing, feeling ill, as well as use of analgesics, nutritional supplements, feeding tube and finally, weight gain and weight loss. All of the scales and single item measures range in score from 0 to 100. High scores for the Global Health Status/QoL scale represent high QoL, high scores for the functional scales represent high/healthy levels of functioning, but high scores for the symptom scales/items represent high levels of symptomatology/problems. Scoring the two instruments yields a total of 33 distinct scores and we will examine all of these scored.
Study NCT05307939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MDADI-HN
Description: The MDADI-HN is a questionnaire scored on a scale of 1 to 5, consisting of global, emotional, functional, and physical subscales. The MDADI-HN evaluates the effects of dysphagia on QOL.
Study NCT05307939 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COST-FACIT
Description: Comprehensive Score for financial Toxicity or COST survey is a validated screening tool to assess objective and subjective questions about treatment-related financial distress. It is scored from 0-44, where lower composite scores reflect greater risk of financial toxicity.
Study NCT05307939 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy (Arm A)
Description: 59.4-60 Gy in 1.8-2 Gy fractions: CTV_primary, Involved/Adjacent to nodal levels. 50 Gy to this volume is allowed as per MSK institutional standards in patients with clear or close margins and 2-4 involved nodes. 45-50.4 Gy in 1.8-2 Gy fractions: Dissected node positive neck: uninvolved levels that are not adjacent to positive node - Dissected node negative neck
Study NCT05307939 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiation (Arm B)
Description: 30 Gy in 2 Gy fractions: CTV_primary, CTV_node-positive neck, CTV_node-negative neck, received de-escalated postoperative chemoradiation. Adjuvant radiation will be administered as previously outlined. Concurrent chemotherapy will be administered as per standard of care. Cisplatin will be administered concurrently with radiation. For non-cisplatin candidates, carboplatin/5fu will be administered. Reasons for using carboplatin/5FU instead of cisplatin need to be charted in the medical record, but the decision belongs to the treating physician. Cisplatin may be given up to 3 days before the scheduled dates, if necessary for medical or personal reasons
Study NCT05698927 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
Description: Comparison of the postoperative opioid consumptions between Erector Spinae Plane Block (bilaterally, via 20ml % 0.25 bupivacain) and Intrathecal Morphine (100 mcg)
Study NCT06048094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F fluciclovine
Description: Participants will receive 5-mCi dose (± 20%) of 18F-fluciclovine intravenously as a bolus injection immediately prior to PET data acquisition. PET data will be collected in list mode up to 25 minutes post-injection. PET images will be reconstructed in two ways: as a standard static image of data acquired between 10 to 20 minutes post-injection, and as a dynamic series of four 5-minute frames between 5 to 25 minutes post-injection to allow for motion assessment and correction and time-dependent observations.
Study NCT04240288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided antibiotic treatment
Description: Antibiotics will be administered based on the procalcitonin lab results.
Study NCT04240288 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care Antibiotic Treatment
Description: Antibiotics will be administered based on standard of care treatment. The treating physicians will determine the treatment course.
Study NCT04979832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF, fosfomycin and metronidazole
Description: GM-CSF 50 micrograms Fosfomycin 400 milligrams Metronidazole 100 milligrams applied as a gel in the pouch
Study NCT05512208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib (VS-6766) + defactinib
Description: Avutometinib (VS-6766): will be administered at 3.2 mg orally twice a week Defactinib: will be administered at 200 mg orally twice a day (BID).~Treatment will be for 3 weeks, followed by a 1-week rest period, in each 4-week (28 day) cycle.
Study NCT05383729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: learning-curve-based training modality
Description: It is an individual duration of simulation training that is based on the previous performance of FOB on a simulator.
Study NCT05383729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fixed-training-time training modality
Description: It is a training duration of 1 hour which is the dominant duration of simulator training in previous studies.\[1\]
Study NCT05012852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VagiVitalAC
Description: In the Pilot part, the single intervention used is VagiVitalAC treatment for 30 days. In the randomized part, patients in the Interventional arm are treated with VagiVital AC for up to 90 days.
Study NCT05519046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac Contractility Modulation (CCM)
Description: Cardiac Contractility Modulation (CCM) implantation
Study NCT05519046 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Cardiac Resynchronization Therapy
Study NCT04565288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Participants randomized to receive the study medication, atomoxetine (brand name: Straterra) for 6-weeks (40 mg/day for 3 days then 80 mg/day thereafter). A comparator group will receive placebo (sugar pills).
Study NCT04565288 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo (sugar pill)
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Set physical activity goals
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Participate in a one-on-one interview
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: View private social media peer support group content
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit physical activity tracker
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear a Fitbit physical activity tracker
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear a research grade activity measuring device
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reward
Description: Receive badges
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive text messages
Study NCT06410209 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive reminders
Study NCT04933149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Infustion
Description: Intravenous infusion at 0.5 mg/kg/hr from induction to emergence from anesthesia during the subject's brachial plexus reconstruction surgery. In addition, subjects will receive postoperative ketamine infusion of 0.1-0.3 mg/kg/hr for 24 hours titrated to side effects while patients are admitted to the hospital following surgery.
Study NCT04746599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Fat Grafting
Description: The trochanteric area or the periumbilical abdominal region represents the donor sites. Following Coleman's technique and after the administration of modified Klein solution, a skin incision is performed in the selected area. Adipose tissue is harvested and after suture the area is managed with an elastic-compressive dressing, to be kept in place for 5 days to prevent hematoma formation. The adipose tissue is the centrifuged at 920 × g for 3 min in sterile conditions. Only the intermediate layer containing adipocytes and stromal vascular component will be then injected using a blunt cannula. The terminal branches of the patient's leg arteries are mapped to facilitate graft placement. Under local anesthesia multiple injections of the adipose tissue formulation are inoculated 1 cm above the end of the terminal branch of the peroneal, anterior, and posterior tibial arteries.
Study NCT04275804 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Magnitude High Frequence Vibration Platform
Description: with low-magnitude high-frequency vibration (35Hz, 0.3g peak-to-peak displacement \<0.1mm)
Study NCT04275804 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Dressing
Description: Alternate Day Dressing
Study NCT05688085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan High/Amlodipine FDC
Description: Irbesartan High/Amlodipine FDC
Study NCT05688085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan High
Description: Co-administration of Irbesartan High and Amlodipine
Study NCT05688085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Co-administration of Irbesartan High and Amlodipine
Study NCT04936776 — intervention group
Intervention type: BEHAVIORAL
Intervention: Text messaging
Description: Text parents of children (age 0-2yrs) who are due and due soon for a vaccine across the entire NYU-Brooklyn FHC network to increase vaccination rates.
Study NCT04816747 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous PRP
Description: Participants enrolled in this study will be managed with intradiscal and/or intra-articular injections of autologous PRP according to features of underlying pathology. Participants featuring FJS will be prior to PRP diagnostically and therapeutically injected with local anesthetic in order to verify FJS as the etiology of experienced pain. Injected PRP solution volume is designed to be 0.5-1 ml and 0.5 ml in cases of intradiscal and intra-articular injection, respectively. All participants are planned to receive a single dose of PRP, whilst a maximum of two compromised discs and four facet joints will be treated in each patient.
Study NCT02199015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral spinal cord surgical implant of electrodes
Description: The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.~A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG).
Study NCT05265819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: X-BOX kinetic360
Description: 1) Exergaming The practice of exergaming was performed using the Xbox 360 Kinect console,The volunteers carried out 36 exergaming sessions, with progressive increase in the duration of the games according to their tolerance,and reached a maximum duration of 50 minutes per session, included the realization of the games and the rest between activities. The exergaming protocol was performed two to three times a week, for a total of 12 weeks.